JAGUAR HEALTH, INC. Proceeds from Long-Term Debt Issued
JAGUAR HEALTH, INC. (JAGX) reported Proceeds from Long-Term Debt Issued of $12.30 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2021-03-31
- JAGUAR HEALTH, INC. proceeds from issuance of long-term debt for the quarter ending 2020-12-31 was $11.95M.
- JAGUAR HEALTH, INC. proceeds from issuance of long-term debt for the quarter ending 2018-09-30 was $0.00.
- JAGUAR HEALTH, INC. proceeds from issuance of long-term debt for the quarter ending 2018-06-30 was $0.00.
- JAGUAR HEALTH, INC. proceeds from issuance of long-term debt for the quarter ending 2018-03-31 was $2.31M.
- JAGUAR HEALTH, INC. proceeds from issuance of long-term debt for fiscal 2020 was $12.30M.
- JAGUAR HEALTH, INC. proceeds from issuance of long-term debt for fiscal 2015 was $5.62M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2020-12-31 | $11.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $12.30M 10-K · filed 2021-03-31 | ||
| 2020-09-30 | $350.00K 10-Q · filed 2020-11-16 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-19 | $0.00 derived: sum of 2 quarters · filed 2019-08-14 | $2.31M 10-Q · filed 2018-11-19 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $2.31M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $2.31M 10-Q · filed 2019-05-21 | |||
| 2015-12-31 | -$250.02K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $5.62M 10-K · filed 2017-02-15 | ||
| 2015-09-30 | $5.87M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |